KR970704445A - 페노티아진 및/또는 티옥산틴을 사용한 알츠하이머 병의 치료 및/또는 예방 방법(methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes - Google Patents

페노티아진 및/또는 티옥산틴을 사용한 알츠하이머 병의 치료 및/또는 예방 방법(methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes

Info

Publication number
KR970704445A
KR970704445A KR1019970700943A KR19970700943A KR970704445A KR 970704445 A KR970704445 A KR 970704445A KR 1019970700943 A KR1019970700943 A KR 1019970700943A KR 19970700943 A KR19970700943 A KR 19970700943A KR 970704445 A KR970704445 A KR 970704445A
Authority
KR
South Korea
Prior art keywords
thioxanthenes
phenothiazines
disease
treating
preventing alzheimer
Prior art date
Application number
KR1019970700943A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of KR970704445A publication Critical patent/KR970704445A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1019970700943A 1994-08-08 1997-02-10 페노티아진 및/또는 티옥산틴을 사용한 알츠하이머 병의 치료 및/또는 예방 방법(methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes KR970704445A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28733994A 1994-08-08 1994-08-08
US34675794A 1994-11-30 1994-11-30
PCT/US1995/010110 WO1996004915A1 (en) 1994-08-08 1995-08-07 Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes

Publications (1)

Publication Number Publication Date
KR970704445A true KR970704445A (ko) 1997-09-06

Family

ID=26964404

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970700943A KR970704445A (ko) 1994-08-08 1997-02-10 페노티아진 및/또는 티옥산틴을 사용한 알츠하이머 병의 치료 및/또는 예방 방법(methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes

Country Status (5)

Country Link
EP (1) EP0778773A1 (ko)
KR (1) KR970704445A (ko)
AU (1) AU708682B2 (ko)
CA (1) CA2196529A1 (ko)
WO (1) WO1996004915A1 (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB9713484D0 (en) * 1997-06-27 1997-09-03 Smithkline Beecham Plc Neuroprotective vanilloid compounds
DE19842416A1 (de) * 1998-09-16 2000-04-13 Max Planck Gesellschaft Sekundäre Amine zur Prävention und Therapie von Erkrankungen, die durch Oxidationsprozesse verursacht oder verstärkt werden
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
ES2272911T3 (es) * 2003-04-25 2007-05-01 Neurofit Sas Uso de derivados de fenotiazina piperazina en la fabricacion de un medicamento con efectos neuroprotector y/o neurotroficos sobre cns y/o pns.
CN101084204B (zh) 2004-09-23 2012-12-05 卫思道制药有限公司 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法
CA2592320C (en) 2004-12-22 2015-11-24 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
AU2007231126B2 (en) 2006-03-29 2012-11-01 Wista Laboratories Ltd. Inhibitors of protein aggregation
EP2853293B1 (en) * 2006-03-29 2017-11-22 WisTa Laboratories Ltd. Thioninium compounds and their use
PT2013191E (pt) 2006-03-29 2010-10-29 Wista Lab Ltd Sais de 3,7-diamino-10h-fenotiazina e a sua utilização
CA2666246C (en) 2006-10-12 2013-12-31 Bellus Health (International) Limited Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
ES2331282B1 (es) * 2008-06-25 2010-10-21 Consejo Superior De Investigaciones Cientificas (Csic) (45%) Hidrazidas de sistemas heterociclicos y su uso en el tratamiento de enfermedades neurodegenerativas.
DE102010062810B4 (de) * 2010-09-07 2014-03-13 Immungenetics Ag 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien
US9283230B2 (en) 2011-02-11 2016-03-15 Wista Laboratories Ltd. Phenothiazine diaminium salts and their use
US8980884B2 (en) * 2011-06-01 2015-03-17 Wisconsin Alumni Research Foundation Methods for treating Alzheimer's disease
JP2023549174A (ja) * 2020-11-04 2023-11-22 グリアセルテック・インコーポレイテッド クロルプロマジンを含む神経炎症性疾患の予防または治療用組成物
WO2022104070A2 (en) * 2020-11-13 2022-05-19 Icahn School Of Medicine At Mount Sinai Phenothiazine compounds for the treatment of alzheimer's disease and other age-related and neurological diseases
WO2023131606A1 (en) * 2022-01-04 2023-07-13 Immungenetics Ag Specific dosage of phenothiazine compounds for use in treatment or prevention of alzheimer's dementia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2837518A (en) * 1958-06-03 Phenthiazine compounds
US2902484A (en) * 1954-04-27 1959-09-01 Rhone Poulenc Sa Phenthiazine derivatives and processes for their preparation
NL108827C (ko) * 1956-04-09

Also Published As

Publication number Publication date
WO1996004915A1 (en) 1996-02-22
CA2196529A1 (en) 1996-02-22
AU3279395A (en) 1996-03-07
EP0778773A1 (en) 1997-06-18
AU708682B2 (en) 1999-08-12

Similar Documents

Publication Publication Date Title
KR970704445A (ko) 페노티아진 및/또는 티옥산틴을 사용한 알츠하이머 병의 치료 및/또는 예방 방법(methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
EP0951293A4 (en) METHOD FOR TREATING ALZHEIMER DISEASE
DE69838789D1 (de) Verfahren zur behandlung oder prävention der alzheimerischen krankheit
NO944928D0 (no) Fremgangsmåter for inhibering av Alzheimers sykdom
EP0587377A3 (en) Thiazolidinone derivatives as hypoglycemic agents and for treating alzheimer's disease
EP0735870A4 (en) USE OF PHOSPHOLIPASE-A2 INHIBITORS FOR TREATING ALZHEIMER'S DISEASE
HU9600596D0 (en) Method of treating cardiac in flammatory disease
EP1043991A4 (en) TREATMENT OF ALZHEIMER DISEASE
AU2830097A (en) Therapeutic method for treatment of alzheimer's disease
NO20010593D0 (no) Preparat og fremgangsmåte for behandling av Peyronie's sykdom og andre subdermale plakkmanifestasjonsforstyrrelser
EP0613560A4 (en) METHOD FOR DIAGNOSING AND TREATING ALZHEIMER'S DISEASE.
DE69731468D1 (de) Einrichtungen zum erzeugen von zusammengesetzten krümmungen in distalen katheterregionen
NO972451D0 (no) 2-heterocyklyloksy og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og fremgangsmåte for anvendelse derav
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
FI953915A (fi) Dupuytrenin taudin lievittämiseen
IL114466A0 (en) A method for treating and preventing alzheimer's disease
IL135584A0 (en) Method for treating alzheimer's disease
ZA978557B (en) Process for the determination of APP secretase modulators and the use thereof as agents in the treatment of a Alzheimer's disease.
DE69514960T2 (de) Schlackbehandlungssystem und -methode
IL117695A0 (en) Pharmaceutical agents for the treatment of alzheimer's disease
ZA971716B (en) 1,1,2-triphenylbut-1-ene derivatives for treating alzheimer's disease
EP0866799A4 (en) APOLIPOPROTEIN E2 AND TREATMENT OF ALZHEIMER'S DISEASE
EP0866717A4 (en) Oligodendrocyte specific protein and method for treating diseases
FI973367A (fi) Menetelmä ja laite ongelmajätteen käsittelemiseksi
GB9709416D0 (en) Methods for treatment of alzheimer's disease using azaspiranes

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid